Biogen, Eisai in Alzheimer's pact

Share this article:

Biogen Idec and Tokyo-based Eisai announced today that they will collaborate and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401. E2609 has completed Phase-I trials. BAN2401 is now recruiting for Phase II.

The agreement also includes an option to jointly develop and commercialize two of Biogen Idec's candiates for Alzheimer's, anti-amyloid beta antibody BIIB037, currently in Phase I, and an anti-tau monoclonal antibody.

Biogen CEO George Scangos stated, "Eisai's candidates have demonstrated compelling early data and complement our AD research while extending our pipeline in this critical area." 

Eisai will act as the operational and regulatory lead for both E2609 and BAN2401, and as its role suggests, will pursue marketing authorization for both compounds.

The companies will share costs, including R&D expenses, and Eisai retains all potential sales for E2609 and BAN2401, but profits will be split between the two. In the US and EU, Eisai and Biogen will co-promote the products, if approved.

Biogen will provide Eisai with an up-front payment, as well as development, approval and commercial milestone payments.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.